Blinding integrity in psychedelic research: Evidence from a comparative randomized controlled trial of psilocybin, MDMA, and methylphenidate in healthy volunteers

EUROPEAN NEUROPSYCHOPHARMACOLOGY · Published 2026-05-28 · DOI 10.1016/j.euroneuro.2026.112879

Free full text

Authors (11)

L. Belinger, N.M. Rieser, E.J.E. Engeli, L. Becciolini, M. Clamote, M. Pribis, F. Saissi, G.A. Florineth, N.L. Hehl, M. Herdener, K.H. Preller

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Belinger, L., Rieser, N., Engeli, E., et al. (2026). Blinding integrity in psychedelic research: Evidence from a comparative randomized controlled trial of psilocybin, MDMA, and methylphenidate in healthy volunteers. EUROPEAN NEUROPSYCHOPHARMACOLOGY. https://doi.org/10.1016/j.euroneuro.2026.112879

Related articles

• Effectiveness of GLP-1RA vs metformin for diabetes prevention in antipsychotic-treated patients · EUROPEAN NEUROPSYCHOPHARMACOLOGY · 2026 · Same journal
• Complexity or simplicity? A replication analysis of low heart rate as a predictor of TMS response in major depressive disorder · EUROPEAN NEUROPSYCHOPHARMACOLOGY · 2026 · Same journal
• A call for the systematic assessment of sexual adverse events in ketamine and esketamine trials and clinical practice · EUROPEAN NEUROPSYCHOPHARMACOLOGY · 2026 · Same journal
• When clinical trials fail to represent patients: implications for schizophrenia guidelines · EUROPEAN NEUROPSYCHOPHARMACOLOGY · 2026 · Same journal
• Prevalence and outcomes of co-occurring psychiatric and neurological disorders: An atlas based on umbrella review of 81 meta-analyses · EUROPEAN NEUROPSYCHOPHARMACOLOGY · 2026 · Same journal
• Long-term adjunctive lumateperone 42 mg treatment in major depressive disorder: Results from a 6-month open-label extension study · EUROPEAN NEUROPSYCHOPHARMACOLOGY · 2026 · Same journal
• Involuntary movements integral to psychotic illness: a ‘circular epistemological journey’ informing the pathobiology and treatment of psychosis and reconceptualising tardive dyskinesia · EUROPEAN NEUROPSYCHOPHARMACOLOGY · 2026 · Same journal
• Rethinking neurocognitive and cardiometabolic screening in severe mental illness · EUROPEAN NEUROPSYCHOPHARMACOLOGY · 2026 · Same journal
• Dissecting the shared genetic architecture of ADHD and substance use disorders: Promising leads and persistent challenges · EUROPEAN NEUROPSYCHOPHARMACOLOGY · 2026 · Same journal
• Perinatal bipolar disorder as a critical risk window: rationale for hospitalization at home on this population · EUROPEAN NEUROPSYCHOPHARMACOLOGY · 2026 · Same journal